Diabetic ketoacidosis

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

JDRF Applauds Usher and NFL Star Noah Gray for Shining a Spotlight on Type 1 Diabetes at Super Bowl LVIII

Retrieved on: 
Monday, February 12, 2024
JDRF, Diabetes, Kansas City Chiefs, Super Bowl LVIII, Autoimmune disease, Research, Usher, Dream, Blood, Diabetic ketoacidosis, Super Bowl, Hospital, Sport, Risk, Autoantibody, Bowl game, Duke University, Pancreas, Insulin, Knowledge, Disease, T1D, Child, Diagnosis, SAN, NFL, DKA, Immune system, Pharmaceutical industry

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is recognizing Grammy award-winning megastar Usher and NFL Super Bowl Champion Noah Gray of the Kansas City Chiefs for shining a spotlight on T1D during Super Bowl LVIII.

Key Points: 
  • NEW YORK, Feb. 12, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is recognizing Grammy award-winning megastar Usher and NFL Super Bowl Champion Noah Gray of the Kansas City Chiefs for shining a spotlight on T1D during Super Bowl LVIII.
  • As Usher prepared for his highly anticipated Super Bowl Halftime Show and the release of his forthcoming album, he also prioritized raising awareness for T1D and the importance of screening.
  • "Usher's advocacy has played a crucial role in raising awareness about type 1 diabetes and the importance of early detection through screening," said Aaron Kowalski, CEO of JDRF.
  • Noah Gray, a standout tight end for the NFL Kansas City Chiefs, was diagnosed with T1D during his freshman year at Duke University.

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Diarrhea, Marketing, Diabetes, INN, Diabetic ketoacidosis, Allergy, ATC, International, Pancreas, Insulin, Disease, Language, Blood, Porphyrin, Mellitus, Glycated hemoglobin, Mouth, Blood sugar level, Infant, Abdominal pain, Porphyria, KATP, European Medicines Agency, ATP, Tablet, Chronic pain, Select, Cell, Patient, Time, Anatomy, Medicine, IIA, Neonatal diabetes, Hypoglycemia, Life, Medical device

Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 8, Status: Authorised

Survey: 2/3 of Parents Unaware that Type 1 Diabetes is Identifiable Before Symptoms

Retrieved on: 
Thursday, December 7, 2023
Insulin, Incidence, Risk, Disease, Diabetic ketoacidosis, Autoimmune disease, Parent, Diagnosis, Diabetes, DLC, DKA, Medical device, Residential care, Nursing, T1D

WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- A new national survey commissioned by the Diabetes Leadership Council (DLC) found that nearly 2/3 (62%) of parents are unaware that type 1 diabetes (T1D) can be identified before symptoms occur. The findings come at a time when T1D is typically diagnosed in the final of three stages when a person begins experiencing symptoms, blood sugar is high, and insulin dependence begins.

Key Points: 
  • WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- A new national survey commissioned by the Diabetes Leadership Council (DLC) found that nearly 2/3 (62%) of parents are unaware that type 1 diabetes (T1D) can be identified before symptoms occur.
  • In DLC's online survey of 1,000 parents of children aged 17 and younger, findings indicate that parents may misunderstand T1D risk and are unaware of screening options to identify risk early.
  • Only one-third (38%) of parents surveyed are aware that risk for T1D can be identified before experiencing symptoms.
  • Parents should talk with their family doctor about screening options to learn which option may be right for them.

Nick Jonas and Beyond Type 1 Launch #SeeTheSigns, a National Campaign to Help People Recognize the Symptoms of Diabetes and Receive a Diagnosis

Retrieved on: 
Monday, November 13, 2023
Choking, National Diabetes Education Program, Kidney disease, Risk, Amputation, Diabetic ketoacidosis, Stroke, Urination, Social media, Health, Thirst, Diabetes, Diagnosis, Death, Health education, Prediabetes, Life, Diabetic coma, Weight loss, DKA, Pharmaceutical industry

SAN MATEO, Calif., Nov. 13, 2023 /PRNewswire/ -- For the 8.5 million American adults living with undiagnosed diabetes, recognizing the symptoms can determine the difference between life and death—and greatly reduce the likelihood of long-term complications due to a missed or delayed diagnosis.

Key Points: 
  • To address this epidemic crisis, Beyond Type 1 today announced #SeeTheSigns, a national campaign to help people effectively identify the symptoms of diabetes in themselves and others.
  • Unlike the signs of a stroke, choking and other life-threatening emergencies, the symptoms of diabetes often go unnoticed and unaddressed for some time.
  • "I was lucky to receive my diagnosis at age 13 when my mom noticed the signs —but many aren't as lucky.
  • While type 2 diabetes is more common, it's only diagnosed in about half of those whose bodies show symptoms.

Bexacat™ (bexagliflozin tablets), the First and Only Tablet to Treat Feline Diabetes, Named “Overall Cat Health Product Of The Year” In 2023 Pet Innovation Awards

Retrieved on: 
Thursday, November 2, 2023
Science, FDA, Research, Retail, Veterinarian, NYSE, Innovation, Food, Diabetes, Vomiting, Human, Cat, Weight loss, Diarrhea, Elanco, Service, DM, SGLT2, Argyreia nervosa, Liver, Type 1 diabetes, Pancreatitis, ELAN, Urine, Dehydration, Disease, Risk, Farmer, Lethargy, Depression, Diabetic ketoacidosis, Pet, Diagnosis, Death, Glucose, Coma, Insulin, Pharmaceutical industry, Health, Housing

Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).

Key Points: 
  • Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).
  • “Bexacat removes some of the traditional challenges associated with treating feline diabetes and is a more efficient option for today’s on-the-go pet owner lifestyle.
  • Bexacat is needle-free and dosed to felines at a minimum weight of 6.6 lbs in order to ensure dosing accuracy.
  • The 2023 Pet Innovation Awards attracted more than 2,000 nominations from around the world.

Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis

Retrieved on: 
Wednesday, October 18, 2023
Cardiac arrest, Volatile organic compound, Kidney, Diabetes, DKA, Qi, Ketone, Cell, Type 1 diabetes, Acetone, VOC, Type 2 diabetes, Diabetic ketoacidosis, Patient, Death, Coma, Insulin, Pharmaceutical industry, Medical device

DKA is a serious complication of diabetes that can be life-threatening. DKA is most common among children with Type 1 diabetes, however adults with Type 2 diabetes can also develop DKA. DKA occurs when the insulin level drops rapidly and can’t drive blood sugar into the cells for use as fuel supply. Under this condition, the liver starts to break down fat for energy -- a process that generates acidic substances called ketones, which can accumulate to dangerous levels in the body. Acetone is a volatile ketone which can be detected in the breath. If left untreated, DKA can escalate within 24 hours into life-threatening conditions such as brain swelling, cardiac arrest, kidney damage, coma and death.

Key Points: 
  • FREEHOLD, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it has partnered with Qi Diagnostics Limited (“Qi Diagnostics”) to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for the early detection of diabetic ketoacidosis (“DKA”).
  • Qi Diagnostics has developed DKAir™ a handheld breathalyzer that allows diabetic patients to blow into the breathalyzer to detect the acetone levels in their breath.
  • We are excited to partner with Qi Diagnostics to co-develop international multi-center clinical studies for DKAir™.
  • The preclinical research has been completed and we expect the clinical studies to start in the first quarter of 2024.”

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, Fatal, Weakness, Female, Skin, PD-L1, Creatinine, DKA, Nausea, Swelling, Keratitis, Pneumonia, Birth, PD-1, Hair, Neutrophil, Male, Peripheral neuropathy, Lipase, Acute kidney injury, Blood, Stevens–Johnson syndrome, Toxic epidermal necrolysis, Diabetic neuropathy, Toxicity, Bulla, Temperature, Appetite, Itch, SJS, Fetus, Cornea, Conjunctivitis, Hyperglycemia, Dermatitis, Evaluation, Hypoxia, Pain, Diabetic ketoacidosis, Pembrolizumab, ILD, Risk, Liver, Lymphocyte, Grade 2, Rash, Erythema, Fatigue, Acral lentiginous melanoma, Pneumonitis, Papule, Incidence, Dysgeusia, Anemia, Cough, Urinary tract infection, Diarrhea, Erythroderma, Periodic breathing, TEN, Patient, MUC, PN, Drug eruption, Septic shock, Pharmaceutical industry, Medical imaging, Palladium

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.

Key Points: 
  • Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.
  • When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate.
  • Skin reactions occurred in 72% (all grades) of the 121 patients treated with PADCEV in combination with pembrolizumab in clinical trials.
  • The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash.

NFL Cincinnati Bengals' Orlando Brown, Jr. Embarks on New Role as JDRF Ambassador, Championing Type 1 Diabetes Awareness

Retrieved on: 
Tuesday, September 26, 2023
Knowledge, JDRF, Uncertainty, NFL, Insulin, History of the Cincinnati Bengals, Diabetes, Education, Hospital, SDP, Pancreas, Hope, Research, Federal, Diabetic ketoacidosis, Congress, Super Bowl, Risk, Diagnosis, Cincinnati Bengals, Disease, Pharmaceutical industry, Management, T1D

CINCINNATI, Sept. 26, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce NFL Super Bowl Champion and Cincinnati Bengal Orlando Brown, Jr.'s appointment as an ambassador to the organization. Orlando's new role will be announced at a T1D community event hosted by JDRF and the Cincinnati Bengals at Payor Stadium on September 28. The celebratory event will bring together Orlando's football family and adults and children living with T1D in Cincinnati. Orlando's commitment to T1D advocacy stems from his family's journey with the disease. It began with his grandmother's diagnosis with T1D, followed by the devasting loss of his father, NFL player Orlando Brown, Sr., to diabetic ketoacidosis, a serious diabetes complication. His younger brother's T1D diagnosis at just 11 years old fueled Orlando's' determination to advocate for more research, T1D education, and access to diabetes technologies and therapies that make life easier and safer for people with T1D.

Key Points: 
  • CINCINNATI, Sept. 26, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce NFL Super Bowl Champion and Cincinnati Bengal Orlando Brown, Jr.'s appointment as an ambassador to the organization.
  • Orlando's new role will be announced at a T1D community event hosted by JDRF and the Cincinnati Bengals at Payor Stadium on September 28.
  • "Type 1 diabetes has deeply impacted my family," said Orlando Brown, Jr., NFL Cincinnati Bengals.
  • With his infectious smile and steadfast determination, Orlando immediately stepped up to collaborate in his new role as JDRF ambassador.

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

Retrieved on: 
Friday, September 22, 2023
Hypersensitivity, Medical Affairs Bureau, Kidney failure, University, Chronic kidney disease, Hospital, EGFR, Glomerular filtration rate, Diabetes, Diabetic ketoacidosis, Angioedema, History, Kidney disease, Dialysis, Tablet, Boehringer Ingelheim, Transplant, Prednisone, Excipient, LLY, Polycystic kidney disease, Translational Health Science and Technology Institute, HIV disease progression rates, Patient, Risk, University of Washington Medical Center, Eli Lilly and Company, Region, Research, FDA, EMPA, CKD, III, News, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Dietary supplement, Pharmaceutical industry, Medicine

Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.

Key Points: 
  • Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.
  • "The meaningful benefits that empagliflozin demonstrated in the EMPA-KIDNEY phase III trial are welcome news for adults living with CKD in this country."
  • EMPA-KIDNEY was a large trial designed to reflect the broad range of adults with CKD with or without type 2 diabetes.
  • *Kidney disease progression: Defined as end-stage kidney disease (the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decline in estimated glomerular filtration rate (eGFR) to below 10 mL/min/1.73 m2, kidney death or a sustained decline of at least 40% in eGFR from randomization).